uTREAT
Tracked across 1 events · 6 articles · First seen Jun 08, 2026 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: uTREAT is Curasight's targeted radioligand therapy being investigated in a Phase 1 clinical trial for glioblastoma, showing promising preliminary results.
Jun 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track uTREAT live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard